The longest reported survival of ALK1-related PAH that we could find was approximately 25 years in a patient treated with multiple agents, including subcutaneous prostacyclin and low-dose tacrolimus [12]. This evidence concerns the gene ACVRL1 and pulmonary arterial hypertension.